InflaRx Announces Pricing of $75 Million Public Offering of Common Shares and One-Year Warrants
February 25 2021 - 8:30AM
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical
company developing anti-inflammatory therapeutics by targeting the
complement system, announced today the pricing of its underwritten
public offering of 15,000,000 common shares and warrants. The
shares are being sold at a public offering price of $5.00 per
share. For each common share purchased, an investor will also
receive a warrant to purchase a common share at an exercise price
of $5.80. The warrants are exercisable immediately and have a term
of up to one year. The gross offering proceeds to InflaRx from this
offering are expected to be approximately $75 million, before
deducting the underwriting discount and other estimated offering
expenses and excluding the exercise of any warrants. The Company
intends to use the net proceeds from the offering primarily to fund
research and development expenses for its clinical and preclinical
research and development activities and for working capital and
general corporate purposes.
Guggenheim Securities, LLC and Raymond James
& Associates, Inc. are serving as joint book-running managers
for the proposed offering.
A shelf registration statement relating to the
securities being sold in this offering was filed with the U.S.
Securities and Exchange Commission (the “SEC”) and was declared
effective by the SEC on July 17, 2020. The offering will be made
only by means of a prospectus and prospectus supplement. A
preliminary prospectus supplement and accompanying prospectus
related to the offering have been filed with the SEC and are
available at the SEC’s website located at www.sec.gov. Copies of
the preliminary prospectus supplement and accompanying prospectus
related to the offering may be obtained by contacting Guggenheim
Securities, LLC, Attention: Equity Syndicate Department, 330
Madison, 8th Floor, New York, NY 10017, or by telephone at (212)
518-9544, or by email to
GSEquityProspectusDelivery@guggenheimpartners.com. The final terms
of the offering will be disclosed in a final prospectus supplement
to be filed with the SEC.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities, nor
shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About InflaRx N.V.:
InflaRx (Nasdaq: IFRX) is a clinical-stage
biopharmaceutical company focused on applying its proprietary
anti-C5a technology to discover and develop first-in-class, potent
and specific inhibitors of C5a. Complement C5a is a powerful
inflammatory mediator involved in the progression of a wide variety
of autoimmune and other inflammatory diseases. InflaRx was founded
in 2007, and the group has offices and subsidiaries in Jena and
Munich, Germany, as well as Ann Arbor, MI, USA.
Contacts:
InflaRx N.V.Jordan Zwick – Chief
Strategy OfficerEmail: jordan.zwick@inflarx.deTel: +1
917-338-6523
MC Services AGKatja Arnold, Laurie
Doyle, Andreas JungferEmail: inflarx@mc-services.euEurope: +49
89-210 2280US: +1-339-832-0752
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking
statements, including statements about the offering. All statements
other than statements of historical fact are forward-looking
statements, which are often indicated by terms such as “may,”
“will,” “should,” “expect,” “plan,” “anticipate,” “could,”
“intend,” “target,” “project,” “believe,” “estimate,” “predict,”
“potential” or “continue” and similar expressions. Forward-looking
statements appear in a number of places throughout this release and
may include statements regarding our intentions, beliefs,
projections, outlook, analyses and current expectations concerning,
among other things, our ongoing and planned preclinical development
and clinical trials; the impact of the COVID-19 pandemic on the
Company; the timing and our ability to commence and conduct
clinical trials; potential results from current or potential future
collaborations; our ability to make regulatory filings, obtain
positive guidance from regulators, and obtain and maintain
regulatory approvals for our product candidates; our intellectual
property position; our ability to develop commercial functions;
expectations regarding clinical trial data; our results of
operations, cash needs, financial condition, liquidity, prospects,
future transactions, growth and strategies; the industry in which
we operate; the trends that may affect the industry or us and the
risks uncertainties and other factors described under the heading
“Risk Factors” in InflaRx’s periodic filings with the Securities
and Exchange Commission. These statements speak only as of the date
of this press release and involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. Given these risks,
uncertainties and other factors, you should not place undue
reliance on these forward-looking statements, and we assume no
obligation to update these forward-looking statements, even if new
information becomes available in the future, except as required by
law.
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Apr 2023 to Apr 2024